KR20010044676A - Compositions for cleaning the liver - Google Patents

Compositions for cleaning the liver Download PDF

Info

Publication number
KR20010044676A
KR20010044676A KR1020010013436A KR20010013436A KR20010044676A KR 20010044676 A KR20010044676 A KR 20010044676A KR 1020010013436 A KR1020010013436 A KR 1020010013436A KR 20010013436 A KR20010013436 A KR 20010013436A KR 20010044676 A KR20010044676 A KR 20010044676A
Authority
KR
South Korea
Prior art keywords
weight
gallstones
grape juice
formulation
composition
Prior art date
Application number
KR1020010013436A
Other languages
Korean (ko)
Inventor
김형식
김정식
김춘숙
Original Assignee
김형식
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김형식 filed Critical 김형식
Priority to KR1020010013436A priority Critical patent/KR20010044676A/en
Publication of KR20010044676A publication Critical patent/KR20010044676A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: A composition for eliminating gallstone from the system containing grape juice and olive oil as a main material is provided, which exhibits an excellent effect on treating primary intrahepatic stones etc. CONSTITUTION: This composition comprises a first formulation comprising 97 to 98% by weight of grape juice, 1 to 2% by weight of magnesium sulfate and 0.1 to 1.0% by weight of ascorbic acid, a second formulation comprising 50 to 70% by weight of grape juice and 30 to 50% by weight of olive oil and additionally a third formulation comprising 50 to 60% by weight of a drumstick of chicken, 10 to 30% by weight of a soy bean, 5 to 15% by weight of a pumpkin, 2 to 7% by weight of a ginger, 0.5 to 1.0% by weight of Casssia tora L., 0.5 to 2% by weight of Cnidium officinale Makino, 0.5 to 2% by weight of Angelicae gigantis radix and 0.5 to 2% by weight of cinnamon.

Description

담석 배출용 조성물{Compositions for cleaning the liver}Composition for Gallstone Discharge {Compositions for cleaning the liver}

본 발명은 간내 담석의 체외 배출을 위한 조성물에 관한 것이다.The present invention relates to a composition for extracorporeal discharge of hepatic gallstones.

좀 더 상세하게는 본 발명은 담관 또는 담낭 내에 존재하는 담석을 체외로 배출시키는 데 유용한 포도즙과 올리브유를 주재료로 하는 조성물에 관한 것이다.More specifically, the present invention relates to a composition based on grape juice and olive oil, which are useful for releasing the gallstones present in the bile ducts or gallbladders into the body.

간내 담석은 원발성 간내 담석(primary intrahepatic stones)과 이차적 간내 담석(secondary intrahepatic stones)으로 크게 나누어 볼 수 있다. 원발성 간내 담석이란 담석이 처음부터 간내 담도에서 생성된 것이며 이차적 간내 담석은 담석이 담낭이나 총 담관에서 형성된 후 이차적으로 간내 담관으로 이동한 것을 말한다. 특히 원발성 간내 담석은 결석의 갯수가 많아 보통 한 환자에서도 수 십개 이상의 결석이 발견되고 간내 담도 협착을 동반할 뿐만 아니라 치료가 잘 되지 않는 경우 담도염, 패혈증 및 담즙성 간 경변증 등으로 진행할 수 있는 난치성 질병이다 (Kim et al., Am. J.Gastroenterol. 90: 540-548, 1995).Hepatic gallstones can be roughly divided into primary intrahepatic stones and secondary intrahepatic stones. Primary hepatic gallstones are those in which the gallstones are initially produced in the hepatic biliary tract, and the secondary hepatic gallstones are secondary gallstones that have been formed in the gallbladder or the total bile ducts and then moved to the hepatic bile ducts. In particular, primary hepatic gallstones have a large number of stones, usually ten or more stones are found in one patient, accompanied by biliary stricture in the liver. (Kim et al., Am. J. Gastroenterol. 90: 540-548, 1995).

간내 담석은 여러가지 성분으로 구성되어 있어 그 종류가 다양하다. 담석에는 콜레스테롤이 함유되어 있으며 콜레스테롤 함량은 담석 건조 중량의 약 18.5% 내외이다. 우리나라에서 발견되는 담석은 콜레스테롤 함량이 20%를 넘지 못하는 갈색석(calcium bilirubinate stone)이 대부분이지만 최근에 들어서 기존의 갈색석이외에 콜레스테롤 함량이 50%에 달하는 혼합석이 보고되고 있다.Intrahepatic gallstones are composed of various components, and their types vary. Gallstones contain cholesterol and the cholesterol content is about 18.5% of the dry weight of gallstones. Most gallstones found in Korea are brown calcite (calcium bilirubinate stone) which does not exceed 20% of cholesterol, but recently, mixed stones having 50% cholesterol have been reported.

담석의 종류와 그 위치에 따라 사용되는 현재까지의 치료 방법에 대해 살펴보면, 담낭 결석의 경우 보통 담낭 절제술을이용하여 그리고 총 담관 결석의 경우 내시경을 사용한 결석 제거술을 이용하여 거의 완전한 치료가 가능하다. 그러나 원발성 간내 담석은 다발성 간내 담도의 협착을 동반하고 결석의 수가 많음으로 인하여 결석을 완전히 제거하는 것이 매우어렵다. 실제로 간내 담석의 경우 수술로 완치되는 환자는 대상 환자의 약 20%에 불과하며 나머지 환자들은 반복되는 치료에도 불구하고 간내 담도의 잔류 결석으로 어려움을 겪고 있다.According to the types of gallstones and their current treatment methods, gallstones are usually treated with gallbladder resection and gallstones can be almost completely cured using endoscopic stones. However, primary hepatic gallstones are accompanied by constriction of multiple intrahepatic biliary tracts, and due to the large number of stones, it is very difficult to completely remove the stones. In fact, in the case of hepatic gallstones, only about 20% of patients are cured by surgery, and the remaining patients suffer from residual stones in the biliary tract despite repeated treatment.

이에 본 발명자들은 간내 담석을 체외로 배출시킬 수 있는 조성물을 개발하고자 여러가지 시도를 한 결과 포도즙과 올리브유를 주재료로 한 조성물이 획기적으로 담석을 체외로 배출시키는 효과가 탁월함을 최초로 밝혀 본 발명을 완성하였다.Accordingly, the present inventors have made various attempts to develop a composition capable of releasing intrahepatic gallstones in vitro, and as a result, the composition consisting of grape juice and olive oil as a main ingredient has revealed that the effect of releasing gallstones in vitro is excellent. .

따라서, 본 발명의 목적은 담석을 체외로 배출시키는 데 유용한 조성물을 제공하는 데 있다.Accordingly, it is an object of the present invention to provide a composition useful for the excretion of gallstones in vitro.

도 1은 본 발명의 조성물 섭취 후 배출된 담석의 사진1 is a photograph of the gallstones discharged after ingesting the composition of the present invention

본 발명의 조성물은 포도즙 97-98중량%, 황산 마그네슘 1-2 중량% 및 아스코르빈산 0.1-1.0 중량%로 구성되는 제 1 제제와 포도즙 50-70중량%와 올리브유 30-50중량%로 구성되는 제 2 제제로 구성되는 것을 특징으로 한다.The composition of the present invention comprises a first formulation consisting of 97-98% by weight of grape juice, 1-2% by weight of magnesium sulfate and 0.1-1.0% by weight of ascorbic acid, 50-70% by weight of grape juice and 30-50% by weight of olive oil. It is characterized by consisting of a second agent.

본 발명의 조성물에는 건조중량을 기준으로 계육 50-60중량%, 대두 10-30중량%, 호박 5-15 중량%, 생강 2-7중량%, 결명자 0.5-1.0중량%, 천궁 0.5-2중량%, 당귀 0.5-2중량% 및 육계(계피) 0.5-2중량% 로 구성되는 제 3 제제를 더 포함 할 수 있다.50-60% by weight, 10-30% by weight, 5-15% by weight of pumpkin, 2-7% by weight of ginger, 0.5-1.0% by weight of bladder, 0.5-2% by weight It may further comprise a third agent consisting of%, Angelica 0.5-2% by weight and broiler (cinnamon) 0.5-2% by weight.

본 발명에서 사용한 포도즙은 담낭염, 담석증에 효과가 있다고 알려져 있다. 또, 황산 마그네슘은 강한 삼투압 현상을 일으켜 다량의 담즙의 배출을 유도한다. 식품용으로는 2중량%의 사용량을 넘지 않도록 제하뇌어 있다. 아스코르빈산은 지방분해 효소인 리파아제의 생산을 촉진하여 간내 지방을 분해하여 배출하도록 한다. 1% 미만의 소량의 사용으로도 충분한 효과를 나타낼 수 있다. 포도즙과 황산마그네슘 그리고 아스코르빈산으로 구성된 제 1 제제는 우선 담석 배출을 위한 준비로 간내 지방을 분해하여 배출하고 장내 숙변을 제거하며 괄약근을 열어주는 역활을 한다.Grape juice used in the present invention is known to be effective in cholecystitis, cholelithiasis. In addition, magnesium sulfate causes a strong osmotic phenomenon, leading to the discharge of large amounts of bile. For food use, do not exceed the amount of 2% by weight. Ascorbic acid promotes the production of lipase, a lipolytic enzyme, to break down and release fat in the liver. Small amounts of less than 1% may have sufficient effect. The first formulation, consisting of grape juice, magnesium sulfate, and ascorbic acid, serves to break down and release liver fat, remove bowel stool and open the sphincter in preparation for gallstone discharge.

이어서 포도즙과 올리브유로 구성된 제 2 제제가 담석을 배출시키게 된다. 올리브유는 담석을 제거하기 위한 기름요법이라는 생물학적 치료법에 사용되어 온 기름 중에서 가장 효과가 좋은 식품이다.A second agent, consisting of grape juice and olive oil, then drains the gallstones. Olive oil is the most effective food that has been used in biological therapy called oil therapy to remove gallstones.

계육 , 대두 , 호박 , 생강, 결명자 , 천궁 , 당귀 및 육계(계피) 로 구성되는 제 3 제제를 더 포함 할 수 있다. 제 3 제제는 다량의 아미노산, 특히 아르기닌을 많이 함유하여 담석 등 간에서 배출되는 불순물로 인하여 발생되는 장내 가스를 제거하는 역활을 한다. 또한, 제 1 제제와 제 2 제제는 식사를 하지 않고 공복에 복용하여야 더욱 우수한 효과를 나타내므로 이 제 3 제제가 부족한 영양을 보충하는 역활을 한다.It may further comprise a third agent consisting of poultry, soybean, pumpkin, ginger, missing, cheonggung, donkey and broiler (cinnamon). The third formulation contains a large amount of amino acids, especially arginine, and serves to remove intestinal gas generated by impurities released from the liver such as gallstones. In addition, since the first and second preparations have better effects when taken on an empty stomach without eating, the third preparation serves as a supplement to nutrition lacking.

본 발명을 실시예에 의해 더욱 상세히 설명한다.The present invention will be described in more detail by way of examples.

하기 실시예들은 본 발명을 예시하는 것으로 본 발명의 내용이 실시예에 의해 한정되는 것은 아니다.The following examples are illustrative of the invention and are not intended to limit the scope of the invention.

실시예 1Example 1

조성물의 제조Preparation of the composition

1개의 구성이 포도 과즙 97.7g, 황산 마그네슘 2g, 및 아스코르빈산 0.3g으로 구성된 제 1 제제를 60개 제조한다.Sixty first formulations each consisting of 97.7 g of grape juice, 2 g of magnesium sulfate, and 0.3 g of ascorbic acid were prepared.

1개 구성이 올리브유 33.5g과 포도 과즙 63.5g으로 구성된 제 2 제제를 30개 제조한다.Thirty second formulations were made, one of which consisted of 33.5 g of olive oil and 63.5 g of grape juice.

건조 중량을 기준으로 계육 57%, 대두 20%, 호박 10%, 생강 4.6%, 결명자 0.8%, 천궁 1.1%, 당귀 1.3%, 감초 1.1%, 및 육계 1.1% 로 구성된 원료를 물을 넣고 일반 한약재를 달이는 방식으로 가열하여 추출한 다음 100g 단위로 포장해서 제 3제제를 제조한다.Based on the dry weight, raw materials consisting of 57% broiled chicken, 20% soybean, 10% pumpkin, 4.6% Ginger, 0.8% Cheongung, 1.1%, Angelica 1.3%, licorice 1.1%, and broiler 1.1% After heating by extracting in a manner of sweetening and packaging in 100g units to prepare a third formulation.

실시예 2Example 2

임상 실험Clinical trial

10명의 환자를 대상으로 제 1 일에 오전 6시경 제 3 제제 100g씩을 섭취하게 하고, 오전 10시경 간단한 채식 위주의 식사를 하게 하였다. 12시에 제 3 제제 씩을 섭취하게 한후, 물을 비롯한 일체의 음식물의 섭취를 금하고 오후 6시에 제 1 제제 2개(200g)씩을 섭취하게 하였다. 오후 8시에 다시 제 1 제제 2개(200g)씩을 섭취하게 하였다. 이때부터 환자에 따라서는 배변이 시작되었다. 오후 10시에 제 2 제제 100g과 제 3제제 200g씩을 섭취하게 하였다. 이후 배변에서 담석을 관찰 할 수 있었다.Ten patients were given a dose of 100 g of the third formulation at 6 am on the first day and a simple vegetarian meal at 10 am. After the third formulation was taken at 12 o'clock, the intake of any food including water was prohibited and the first formulation was taken at 2 pm (200 g) at 6 pm. At 8 pm, two first preparations (200 g) were taken again. At this point, some patients began bowel movements. At 10 pm, 100 g of the second preparation and 200 g of the third preparation were taken. Since gallstones could be observed in bowel movements.

제 2 일 오전 6시에 제 1 제제 200g을 섭취하게 하고 8시에 제 2 제제 100g과 제 3제제 200g씩을 섭취하게 하였다. 제 3 일 아침 배변에까지 담석이 배출되었다.On the second day, 200 g of the first agent was taken at 6 am, and 100 g of the second agent and 200 g of the third agent were taken at 8 am. Gallstones were excreted until the bowel movement on the third morning.

배출된 담석의 형태는 환자마다 달랐으며, 크기도 좁쌀 크기에서 대추만한 크기까지 다양하였다. 대개는 녹색 내지 노란색을 띄었고 담즙 색소와 콜레스테롤이 주성분이어서 만져보면 미끈미끈한 기름기 같은 감촉이 있었다.The type of gallstones varied from patient to patient, and varied in size from millet to jujube size. Usually it was green or yellow in color, and its bile pigments and cholesterol were the main ingredients, so it had a greasy, greasy texture.

배출된 담석의 사진을 제 1 도에 게재하였다.A photograph of the discharged gallstones is shown in FIG.

제 3 제제는 이후에도 연속하여 아침 저녁으로 2주일간 복용하는 것이 바람직하고, 2주 후 다시 실시예 2의 과정을 한번 더 반복하는 것이 바람직하다.The third preparation is preferably taken continuously for two weeks in the morning and evening, and it is preferable to repeat the process of Example 2 again two weeks later.

이제까지의 경피적 경로를 통한 결석 제거술은 그 효과가 매우 저조하였는데, 본 발명의 조성물은 수술없이 직접 담석을 체외로 배출시킬 수 있으므로 원발성 간내 담석 등의 치료제로서 매우 우수한 효과를 나타낸다.Thus far, the removal of stones through the percutaneous route has been very poor. The composition of the present invention can directly discharge the gallstones without surgery, and thus shows excellent effects as a therapeutic agent for primary hepatic gallstones.

Claims (2)

포도즙 97-98중량%, 황산 마그네슘 1-2 중량% 및 아스코르빈산 0.1-1.0 중량%로 구성되는 제 1 제제와 포도즙 50-70중량%와 올리브유 30-50중량%로 구성되는 제 2 제제로 구성되는 것을 특징으로 하는 간내 담석의 체외 배출용 조성물.A first formulation consisting of 97-98% by weight of grape juice, 1-2% by weight of magnesium sulfate and 0.1-1.0% by weight of ascorbic acid, and a second agent consisting of 50-70% by weight of grape juice and 30-50% by weight of olive oil. Composition for extracorporeal discharge of hepatic gallstones, characterized in that it is configured. 제 1 항에 있어서, 건조중량을 기준으로 계육 50-60중량%, 대두 10-30중량%, 호박 5-15 중량%, 생강 2-7중량%, 결명자 0.5-1.0중량%, 천궁 0.5-2중량%, 당귀 0.5-2중량% 및 육계(계피) 0.5-2중량% 로 구성되는 제 3 제제를 더 포함하는 것을 특징으로 하는 간내 담석의 체외 배출용 조성물.According to claim 1, 50-60% by weight, 10-30% by weight of soybeans, 5-15% by weight of pumpkin, 2-7% by weight of ginger, 0.5-1.0% by weight of bladder, 0.5-2 weight A composition for extracorporeal discharge of hepatic gallstones, further comprising a third agent consisting of weight percent, 0.5-2% by weight and 0.5-2% by weight of broiler (cinnamon).
KR1020010013436A 2001-03-15 2001-03-15 Compositions for cleaning the liver KR20010044676A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020010013436A KR20010044676A (en) 2001-03-15 2001-03-15 Compositions for cleaning the liver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020010013436A KR20010044676A (en) 2001-03-15 2001-03-15 Compositions for cleaning the liver

Publications (1)

Publication Number Publication Date
KR20010044676A true KR20010044676A (en) 2001-06-05

Family

ID=19706979

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020010013436A KR20010044676A (en) 2001-03-15 2001-03-15 Compositions for cleaning the liver

Country Status (1)

Country Link
KR (1) KR20010044676A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010099460A (en) * 2001-09-29 2001-11-09 서석춘 Cholesterol stones in bile ducts using herbal ingredients
KR20040003916A (en) * 2002-07-04 2004-01-13 신흥철 Drink Composition Having Removal Efficacy of Gallstone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR870004705A (en) * 1985-11-22 1987-06-01 최상환 How to prepare cholelithiasis
KR950024764A (en) * 1994-02-18 1995-09-15 강상모 Alcoholic Disorder Protectors And How To Use Him
KR20000037319A (en) * 2000-04-18 2000-07-05 김연일 Health drink using pomelo
JP2000256152A (en) * 1999-03-05 2000-09-19 Lion Corp Oral composition
KR20020040930A (en) * 2000-11-25 2002-05-31 정 케이 박 존 Manufacturing method of olive powder and composition for olive powder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR870004705A (en) * 1985-11-22 1987-06-01 최상환 How to prepare cholelithiasis
KR950024764A (en) * 1994-02-18 1995-09-15 강상모 Alcoholic Disorder Protectors And How To Use Him
JP2000256152A (en) * 1999-03-05 2000-09-19 Lion Corp Oral composition
KR20000037319A (en) * 2000-04-18 2000-07-05 김연일 Health drink using pomelo
KR20020040930A (en) * 2000-11-25 2002-05-31 정 케이 박 존 Manufacturing method of olive powder and composition for olive powder

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010099460A (en) * 2001-09-29 2001-11-09 서석춘 Cholesterol stones in bile ducts using herbal ingredients
KR20040003916A (en) * 2002-07-04 2004-01-13 신흥철 Drink Composition Having Removal Efficacy of Gallstone

Similar Documents

Publication Publication Date Title
JP2007153888A (en) Internal body purifying composition, foodstuff, bathing agent, cosmetic, pharmaceutical preparation and harmful metal excretion enhancer using it
RU2018101140A (en) COMPOSITIONS, METHODS AND MEDICAL COMPOSITIONS FOR TREATMENT AND HEALTH CARE OF THE LIVER
KR101039589B1 (en) Functional fermented food for improvement of gout
US20030044512A1 (en) Liver function improvement formulation
KR101264245B1 (en) Functional fermented food for improvement of gout
JP2007277128A (en) Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same
Al-Sharafi et al. Ameliorative role of PTU and rosemary leaves extract in male rats with hyperthyroidism.
CN105250913A (en) Medicinal composition for treating fatty liver syndrome of laying hen
KR20010044676A (en) Compositions for cleaning the liver
KR100786122B1 (en) Composition effective for prevention and treatment of obesity which contains crude drug extract
JP2004175680A (en) Mineral-containing composition having improving effect on biological balance
Shanmugasundaram et al. Amrita Bindu—a salt-spice-herbal health food supplement for the prevention of nitrosamine induced depletion of antioxidants
JP2006514041A (en) Composition for suppressing obesity using mixed herbal materials
ES2684579T3 (en) Combinations of extracts of Serenoa repens and lipophilic extracts of Zingiber officinalis and Echinacea angustifolia, their use and the formulations containing them
CN103719552B (en) Feed for preventing and treating swine erysipelas and preparation method for feed
RU2288735C2 (en) Agent, method for its preparing and method for prophylaxis and treatment of small pelvis organs inflammatory disease and rectum disease
KR20020074260A (en) Compositions for excluding waste materials from the body comprising grapefruit juice, Schizandrae Fructus extract and olive oil
KR100536163B1 (en) Compositions for the prevention or treatment of cancer
JP2889921B2 (en) Manufacturing method of granular foods from umeboshi, soy sauce and dandelion dried roots
CN106361938A (en) Traditional Chinese medicine composition for preventing and treating chicken infectious anemia and preparation method and application thereof
CN101214354A (en) Medicament for treating bad smell of feet and beriberi
JP2002187847A (en) Composition for supplying calcium
CN106359659A (en) Composite nutrient blend oil with ulcer restoration effect, and preparation method and application thereof
RU2125886C1 (en) Phytocomplex and method for rendering human organism healthy
KR100579689B1 (en) Compositions for the prevention or treatment of hyperlipidemia

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application